Status:
COMPLETED
VI-1121 for the Treatment Alzheimer's Disease
Lead Sponsor:
VIVUS LLC
Collaborating Sponsors:
Medpace, Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
60-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.
Eligibility Criteria
Inclusion
- clinical diagnosis of Alzheimer's disease
- CT or MRI within 2 years prior to study
- stable dose of current Alzheimer's treatment for at least 3 months
Exclusion
- advanced, severe, progressive or unstable disease
- history of cerebrovascular disease or myocardial infarction within 6 months
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT01428362
Start Date
August 1 2011
End Date
August 1 2013
Last Update
December 11 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco, California, United States, 94109
2
Santa Monica, California, United States, 90404
3
Sunrise, Florida, United States, 33351
4
Louisville, Kentucky, United States, 40217